| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 06/10/2004 | CA2502614A1 Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors |
| 06/09/2004 | EP1426449A1 Method of evaluating degree of canceration of mammal-origin specimen |
| 06/09/2004 | EP1426443A1 Novel human bmcc1 gene |
| 06/09/2004 | EP1426375A2 Analgesic spiroindole derivatives |
| 06/09/2004 | EP1426372A1 2-Oxadiazolechromone derivatives |
| 06/09/2004 | EP1426055A1 Targeted protein degradation vehicles (tpdvs), nucleic acid constructs encoding them and their use |
| 06/09/2004 | EP1426054A1 Medicinal use of histone deacetylase inhibitor and method of evaluating antitumor effect thereof |
| 06/09/2004 | EP1426053A1 Use of amphiphilic lipids for reducing tumor metastasis |
| 06/09/2004 | EP1426052A1 Compositions comprising interleukin-2 and gamma-delta T cell activator and uses thereof |
| 06/09/2004 | EP1426050A1 Jnk inhibitors |
| 06/09/2004 | EP1426047A1 Anti-tumour pharmaceutical composition comprising N-vanillyl fatty acid amide |
| 06/09/2004 | EP1426044A1 Use of esters of L-carnitine or alkanoyl L-carnitines as cationic lipids for the intracellular delivery of pharmacologically active compounds |
| 06/09/2004 | EP1425974A1 A process for tea flower |
| 06/09/2004 | EP1425580A2 Lymphatic endothelial cells materials and methods |
| 06/09/2004 | EP1425413A2 Genes overexpressed in prostate disorders as diagnostic and therapeutic targets |
| 06/09/2004 | EP1425409A2 Hybrid interferon/interferon tau proteins, compositions and methods of use |
| 06/09/2004 | EP1425399A2 Combinatorial methods for inducing cancer cell death |
| 06/09/2004 | EP1425391A1 Therapeutic vaccination method, mutated peptides of hiv reverse transcriptase and their use for vaccination and diagnostic purposes |
| 06/09/2004 | EP1425389A2 Human antibodies specific for interleukin 15 (il-15) |
| 06/09/2004 | EP1425308A2 Polysaccharidic esters of retinoic acid |
| 06/09/2004 | EP1425306A2 Nanoparticles comprising biologically active tnf which is immobilised on the same |
| 06/09/2004 | EP1425303A2 Use of proteins for the production of a medicament for stimulating the innate non specific immune system |
| 06/09/2004 | EP1425284A2 Furo- and thienopyrimidine derivatives as angiogenesis inhibitors |
| 06/09/2004 | EP1425256A1 Method for preparing unsaturated fatty hydroxy-acids and esters thereof, their use in pharmaceutical and/or cosmetic compositions |
| 06/09/2004 | EP1425046A2 Wild-type ras as a cancer therapeutic agent |
| 06/09/2004 | EP1425040A2 In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
| 06/09/2004 | EP1425035A1 Use of biologically active hiv-1 tat, fragments or derivatives thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases |
| 06/09/2004 | EP1425030A2 Non-oxidatively metabolized compounds and compositions, synthetic pathways therefor, and uses thereof |
| 06/09/2004 | EP1425016A2 Compositions and methods of treatment of cancer |
| 06/09/2004 | EP1425012A1 Antihelminthic drugs as a treatment for hyperproliferative diseases |
| 06/09/2004 | EP1425010A1 Substituted indoles and their use as integrin antagonists |
| 06/09/2004 | EP1425002A1 Aryloxypropylamines as chemosensitizing agents in the treatment of cancer |
| 06/09/2004 | EP1424998A1 Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies |
| 06/09/2004 | EP1424960A2 Removable stent and method of using the same |
| 06/09/2004 | EP1424957A2 Microfabricated nanopore device for sustained release of therapeutic agent |
| 06/09/2004 | EP1424942A1 Porphyrins with enhanced multi-photon absorption cross-sections for photodynamic therapy |
| 06/09/2004 | EP1424898A1 Treatment of cancers by inhalation of stable platinum-containing formulations |
| 06/09/2004 | EP1424897A2 Compositions and methods for treatment of cancer |
| 06/09/2004 | EP1424894A2 Inhibition of pathological angiogenesis in vivo |
| 06/09/2004 | EP1424892A2 Modulation of angiogenesis by a-beta peptides |
| 06/09/2004 | EP1424889A2 Method for treating lung cancers |
| 06/09/2004 | EP1251129B1 Pyrimidine derivatives having antitumor effect |
| 06/09/2004 | EP1246824B1 Carboxamide diazepin derivatives, preparation method, use as medicines, pharmaceutical compositions and use thereof |
| 06/09/2004 | EP1235797B1 Aralkyl-1,2-diamines having calcimimetic activity and preparation mode |
| 06/09/2004 | EP1212323B1 Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity |
| 06/09/2004 | EP1148875B1 Methods and compositions to enhance white blood cell count |
| 06/09/2004 | EP1054687A4 Expression vectors and cell lines expressing vascular endothelial growth factor d, and method of treating melanomas |
| 06/09/2004 | EP1000039B1 Substituted quinazoline derivatives and their use as tyrosine kinase inhibitors |
| 06/09/2004 | EP0956294B1 Thrombin inhibitors |
| 06/09/2004 | EP0941737B1 Apoptosis inducers |
| 06/09/2004 | EP0934081B1 Antineoplastic conjugates of albumin |
| 06/09/2004 | EP0809510B1 Lymphotoxin-alpha/beta complexes and anti-lymphotoxin-beta receptor antibodies as anti-tumor agents |
| 06/09/2004 | EP0753053B1 ALPHAVIRUS cDNA VECTORS |
| 06/09/2004 | DE10320633A1 Verfahren zur Identifizierung einer möglichen Modifikation von mindestens einem biologischen Parameter unter Verwendung von lebenden Zellen, die einem Reiz ausgesetzt wurden, und lebenden Zellen, die nicht diesem Reiz ausgesetzt wurden A method of identifying a possible modification of at least one biological parameter using living cells that were exposed to a stimulus, and living cells that were not exposed to this stimulus |
| 06/09/2004 | CN1503794A Inhiitors of cyclin dependent kinases as anti-cancer agent |
| 06/09/2004 | CN1503784A 2-lminopyrrolidine derivatives |
| 06/09/2004 | CN1503782A Certain salts of discodermolide acid pharmaceutical compositions containing them and their use in treating tumors |
| 06/09/2004 | CN1503781A Process for the preparatino of 1,3-substituted indenes and aryl-fused azapolycyclic compounds |
| 06/09/2004 | CN1503774A Carboxylic acid derivative and thereof |
| 06/09/2004 | CN1503679A Anticancer drug-chitosan complex forming self-aggregates and preparation method thereof |
| 06/09/2004 | CN1503678A Use of stimulated peripheral blood mononuclear cells for treating cancerous diseases |
| 06/09/2004 | CN1503673A antiinflammation agents |
| 06/09/2004 | CN1503662A Pharmaceutical preparation |
| 06/09/2004 | CN1502994A Detection and treatment of cancer |
| 06/09/2004 | CN1502629A Anti-angiogenesis and anti-cancer function of angiogenin combined with nucleotide |
| 06/09/2004 | CN1502625A Oligopeptide suppressor of matrix metalloprotease 2 |
| 06/09/2004 | CN1502620A Preparation for sulfuric esterified nanno-oligosaccharide (MOS) cluster compound and use thereof |
| 06/09/2004 | CN1502612A Substituted heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them |
| 06/09/2004 | CN1502608A Hexavalent amino amidate derivative with function of inhibiting blood vessel growth activity |
| 06/09/2004 | CN1502365A Sesame flower extract, preparation method and use thereof |
| 06/09/2004 | CN1502359A Prunella spike oral liquid and preparation process thereof |
| 06/09/2004 | CN1502346A Application of Psoralca corylifolia in anti-infection of helicobacter pyloric and treating relative diseases |
| 06/09/2004 | CN1502343A Pain-eliminating anti-cancer traditional Chinese medicine and preparation process thereof |
| 06/09/2004 | CN1502332A Process for preparing taxol self-emulsified solid nano granule-injection taxol of anti-cancer medicine |
| 06/09/2004 | CN1502331A Anti-angiogenic compositions and methods of use |
| 06/09/2004 | CN1502322A Pharmaceutical dosage form and method of making |
| 06/09/2004 | CN1502320A Moxibustion for treating skin superficial early and intermediate cancer and boil |
| 06/09/2004 | CN1502263A Cancer chemoprotective food products |
| 06/09/2004 | CN1152962C Antiangiogenic peptides derived from plasminogen, its coded polynucleotide and method of inhibiting vascularization |
| 06/09/2004 | CN1152957C Human 6-phosphoglucosamine isomerase, its code sequence and application |
| 06/09/2004 | CN1152881C New indolocarbazole alkaloids from marine actinomycete, its composition and use |
| 06/09/2004 | CN1152871C Hydroxylamine derivative useful for enhancing molecular chaperon prodn. and the prep. thereof |
| 06/09/2004 | CN1152870C Novel taxoids, preparation thereof and pharmaceutical compositions containing same |
| 06/09/2004 | CN1152863C Substituted pyridines as selective coclooxygenase-2-inhibitors and composition thereof |
| 06/09/2004 | CN1152718C Stable oxaliplatin solution preparation and preparation process thereof |
| 06/09/2004 | CN1152716C Farnesyl protein transferase inhbitors with internal radiosensitizing |
| 06/09/2004 | CN1152704C Anticancer oral liquid and its preparing process |
| 06/09/2004 | CN1152691C Use of chemically-stabilized chloride solution for inhibiting antigen-specific immune response |
| 06/09/2004 | CN1152683C Medicinal composition containing naphthyl compound |
| 06/08/2004 | US6747151 Azo compounds for type I phototherapy |
| 06/08/2004 | US6747150 For reducing rate of degradation of proteins in an animal; inhibiting hiv replication |
| 06/08/2004 | US6747061 N-substituted dithiocarbamates for the treatment of biological disorders |
| 06/08/2004 | US6747055 Water-soluble drugs and methods for their production |
| 06/08/2004 | US6747053 Heteroaryl nitriles |
| 06/08/2004 | US6747046 Substituted N-(1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl) derivatives, their production and use as pharmaceutical agents |
| 06/08/2004 | US6747040 Imidazonaphthyridines |
| 06/08/2004 | US6747038 6-amino-11-(trimethoxyphenyl)benzo(c)phenanthridine, 6-amino-11,12-dihydro-11-(trimethoxyphenyl)benzo(c)phenanthrid ine and their salts |
| 06/08/2004 | US6747036 Use of nucleoside analogues (cytosine or 5-fluorocytosine containing compound) useful for acute or chronic myelogenous leukemia |
| 06/08/2004 | US6747035 Antiinflammatory agents; antiallergens |
| 06/08/2004 | US6747031 N-heterocyclic derivatives as NOS inhibitors |